At first glance
I have been concerned regarding the acquisition strategy and raised the issue in other threads - are we really getting value?
The following table is based on company announcements
From today's presentation
The revenue forecast for Smartcorp and Reckon Docs is well short of the revenue declared at the time of purchase.
The other issue has been the heavy R&D spend - the presentation talks of normalising R&D in the coming two years - I will need to do some more work to see if I continue to hold. With all of the money being spent on R&D and Acquisitions it is not positively impacting NPAT or EPS.
Interesting to see institutional holders increasing their support
19/2/2021
17/8/2021
Keen to hear other opinions regarding these issues
